Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

Pfiz­er to make ma­jor in­vest­ment in vac­cine R&D and man­u­fac­tur­ing site in New York

It’s been just over a month since Pfiz­er an­nounced it was pump­ing $120 mil­lion in­to its Michi­gan fa­cil­i­ty to boost Paxlovid pro­duc­tion, and now the Big Phar­ma is mak­ing an­oth­er ma­jor in­vest­ment in vac­cine man­u­fac­tur­ing, this time in its fa­cil­i­ty out­side New York City.

Ac­cord­ing to a re­port from Bloomberg, Pfiz­er is look­ing to sink $470 mil­lion in­to ex­pand­ing its vac­cine re­search fa­cil­i­ties at its lo­ca­tion in Pearl Riv­er, NY, just 25 miles north of New York City. Pfiz­er will con­struct a new build­ing as well as ren­o­vate ex­ist­ing fa­cil­i­ties on the cam­pus. The to­tal ex­pan­sion will be 260,000 square feet with an ad­di­tion­al 55,000 square feet of lab space. The com­pa­ny is aim­ing for con­struc­tion in the first quar­ter of 2026, the re­port said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.